Performance Evaluation of an Ultra-Sensitive Assay for NSCLC Biomarker Testing

Affiches Jun 23, 2025
Oncologie
|
PCR

June 23, 2025

Nathalie Bernard¹, Magdalena Stolarek-Januszkiewicz², Christina Xyrafaki², Ana-Luisa Silva², Justyna Mordaka², Sara Diels¹, Dirk Goossens¹, Lien Heyrman¹, Bart Tegenbos¹, Jurgen Del Favero

Performance Evaluation of an Ultra-Sensitive Assay for NSCLC Biomarker Testing

Featured Resources

See All Experts' Insights
4b7861f8 F33b 433c Acac Afdb1c478b88 0000 791x1024 Brochure
Aug 17, 2026

Genomic Assay List
Header 1024x341 Blogue
Jun 30, 2026

CAR Kinetics in Autoimmune Studies: Expert Insights on Designing Effective Monitoring Strategies | CellCarta
Picture3 Affiches
Mar 3, 2026

Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)
See All Experts' Insights

One global CRO for your whole therapeutic development journey

CellCarta has the multi-modal capabilities, scientific depth, and harmonized global footprint needed to advance even the most complex programs in precision medicine.

Talk to our Team
cta banner